Oncimmune signs contract with Genentech, further demonstrating expanding global footprint for ImmunoINSIGHTS

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has signed a collaboration with Genentech, a member of the Roche Group, to characterise the autoantibody profiles of patients in clinical trials for rheumatological diseases, including Systemic Lupus Erythematosus.

In this new project, Oncimmune will use its proprietary NavigAID™ panel to characterise autoantibody profiles from trial participants.

Following completion of this project, Genentech has the option to expand the contract to profile additional samples.

SLE is a chronic, incurable autoimmune disease associated with multiple symptoms that can flare up over time. Diagnosis of SLE can be challenging. An objective of the project includes better characterisation of the disease, where there is a high unmet need for an effective therapy.

This project builds upon Oncimmune’s broadening commercial footprint to not only deliver diagnostic tests, through EarlyCDT Lung and Liver, but also to partner with large pharmaceutical companies by profiling autoantibodies and developing commercial companion diagnostic tests through Oncimmune’s ImmunoINSIGHTS service business.

Dr Adam M Hill, CEO of Oncimmune said: “Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today. This contract adds to the already substantial pipeline of contracted revenue through our ImmunoINSIGHTS business in FY2021 and provides another opportunity to show how our NavigAID™ technology can assist partners in increasing their ability to better assess where their medicines could make an impact. We look forward to delivering this project and contributing to the scientific understanding of lupus.”

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    Fintel plc

    Fintel core revenue growth is higher than Zeus forecast

    Fintel plc (LON:FNTL), the leading provider of Fintech and support services to the UK retail financial services sector, has released a trading update for the six months to 30 June 2022, which reveals: Core revenue grew

    OnTheMarket Plc

    OnTheMarket analyst Zeus confident in forecasts

    Foxtons, one of London’s leading estate agencies with more than 50 interconnected branches across London, has signed an agreement to advertise its UK residential sales and letting properties at OnTheMarket plc (LON:OTMP). Zeus view: Foxtons, the

    SpaceandPeople analyst Zeus restores estimates and valuation

    SpaceandPeople plc (LON:SAL) secures, sells, and manages flexible space for brand experiences, short term promotions and retailing in high footfall venues for its customers, including in shopping centres and travel hubs. The Group has issued a

    Lookers Plc

    Lookers shares are still undervalued says Zeus

    Lookers plc (LON:LOOK) has released an H1 trading update reporting a continuation of strong performance year to date. H1 2022 underlying PBT is expected to be c. £45m and Management anticipate full year PBT will also

    Inchcape

    Inchcape performance exceeding expectations says Zeus

    Inchcape plc (LON:INCH) has released another positive trading update, with performance exceeding expectations so far this year. This follows on from a positive Q1 update on 28 April. Through quarterly improvement in Distribution volumes and operating

    boohoo Plc

    Boohoo Group analyst Zeus sees a strong performance in Q1

    ¨ Q1 financial highlights: Boohoo Group plc (LON:BOO) revenue of £445.7m is -8.3% YOY vs. a strong comp (Q1 FY22 revenue +32.1%), in line with Zeus’s forecast and management’s previously stated guidance. Gross sales growth remained